Coherus Oncology, Inc. (CHRS)

Coherus Oncology's stock price has been influenced by several events over the past six months. Positive analyst coverage and price target increases, such as Oppenheimer's "Outperform" rating, boosted the stock. Strong clinical data for LOQTORZI, demonstrating improved survival rates in nasopharyngeal carcinoma patients, positively impacted the stock. Promising pipeline developments, particularly regarding Tagmokitug's anticancer properties, acted as a bullish catalyst. Divestitures of the UDENYCA, Cimerli and Yusimry franchises to focus on immuno-oncology pipeline and reduce debt. Strong financial performance in Q3 2024, with increased product revenue and gross profit, and Q1 2024, with increased product revenue. ATM offering and bullish coverage also contributed to stock increase.

Information directly addressing demand seasonality for Coherus Oncology's products and services is limited. Patient demand for LOQTORZI grew in Q1 2025, indicating increasing demand rather than strong seasonality, although a seasonal inventory drawdown was mentioned. The biosimilar market is generally driven by ongoing patient needs and treatment protocols rather than significant seasonal fluctuations. As Coherus shifts its focus more towards innovative oncology therapies, demand will primarily be driven by cancer incidence, diagnosis rates, treatment guidelines, and the efficacy and adoption of its specific oncology products, which are typically less prone to strong seasonal variations.

Coherus Oncology, Inc., established in 2010, is a biopharmaceutical company focused on developing and commercializing immunotherapies for cancer treatment in the United States. The company's key products include LOQTORZI for nasopharyngeal carcinoma, UDENYCA (biosimilar to Neulasta) to reduce infection risk during chemotherapy, Casdozokitug for advanced solid tumors, Tagmokitug for advanced solid tumors, YUSIMRY (biosimilar to Humira) for inflammatory diseases, CIMERLI (biosimilar to Lucentis) for ophthalmic conditions, CHS-1000 for solid tumors, and GSK4381562 targeting CD112R to treat tumor cells. Coherus aims to enhance patient access to innovative and affordable therapies, particularly in the biosimilar market.

Coherus Oncology, Inc. is headquartered in Redwood City, California. Its products are distributed through specialty pharmacies and wholesalers in the United States and select international markets. The company's research and development efforts, including clinical trials, span across North America, Europe, and Asia through partnerships and licensing agreements.

Coherus Oncology's brand reputation has been generally positive, driven by clinical advancements and strategic shifts. Analysts have shown a favorable view of Coherus Oncology, with a consensus rating of "Buy" or "Strong Buy". The successful launch of LOQTORZI and its strong clinical data, along with promising developments in its oncology pipeline, contribute positively to its reputation. The company's strategic focus on innovative cancer drugs and its efforts to expand the market for its PD-1 antibody, LOQTORZI, have been highlighted as positive strategic moves. Divestitures are framed as a strategic move to strengthen its financial position and focus on its immuno-oncology pipeline.

Coherus Oncology, Inc. has a mixed ownership structure. Approximately 22.82% of the company's stock is owned by institutional investors, including BlackRock, Inc. and Vanguard Group Inc. Insiders own about 1.08% of the company's stock. Public companies and individual investors collectively own approximately 76.10% of the stock.